These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30796905)

  • 1. Expression and activity of the cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 is tissue and species-specific.
    Dammann C; Stapelfeld C; Maser E
    Chem Biol Interact; 2019 Apr; 303():57-61. PubMed ID: 30796905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome.
    Loerz C; Maser E
    J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
    Stulnig TM; Waldhäusl W
    Diabetologia; 2004 Jan; 47(1):1-11. PubMed ID: 14652720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
    Morgan SA; Berryman DE; List EO; Lavery GG; Stewart PM; Kopchick JJ
    Growth Horm IGF Res; 2022 Feb; 62():101440. PubMed ID: 34814007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
    Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
    Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice.
    Cobice DF; Livingstone DEW; McBride A; MacKay CL; Walker BR; Webster SP; Andrew R
    Biochem Pharmacol; 2018 Feb; 148():88-99. PubMed ID: 29248595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
    Stimson RH; Andersson J; Andrew R; Redhead DN; Karpe F; Hayes PC; Olsson T; Walker BR
    Diabetes; 2009 Jan; 58(1):46-53. PubMed ID: 18852329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
    Liu Y; Nakagawa Y; Wang Y; Sakurai R; Tripathi PV; Lutfy K; Friedman TC
    Diabetes; 2005 Jan; 54(1):32-40. PubMed ID: 15616008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
    Gathercole LL; Stewart PM
    J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
    Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
    Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
    Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
    J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
    Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.